There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.

有人担心，由于严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 感染导致的 2019 年冠状病毒病 (COVID-19) 全球负担可能会导致格林-巴利综合征 (GBS) 的发生率增加。目前尚不清楚伴随的 SARS-CoV-2 感染和 GBS 是否在病理生理学上相关，哪些生物标志物可用于诊断，以及考虑到医学合并症、并发症和同时感染，最佳治疗方法是什么。我们报告了一名患者在纽约市最初的 COVID-19 激增高峰期（2020 年 4 月）感染 SARS-CoV-2 后出现了严重的 GBS，并讨论了在类似患者中可能需要特别考虑的诊断和管理问题以及并发症。